Moyer GC, Bannow BS, Thornburg C, Rosovsky R, Wang TF, Woller S, Thornhill D, Kreuziger LB. A Survey of Oral Anticoagulant Preferences in the Treatment of Challenging Patient Populations. Clin Appl Thromb Hemost. 2018 Oct 2:1076029618804080. PMID: 30278766.
Rosovsky RP, Sanfilippo KM, Wang TF, Rajan SK, Shah S, Martin KA, Ni Ainle F, Huisman M, Hunt BJ, Khan SR, Kevane B, Lee AYY, McLintok C, Baumann Kreuziger L. Anticoagulation Practice Patterns in COVID‐19: A Global Survey. Research and Practice in Thrombosis and Haemostasis. 2020 Jul 9;4(6):969-83. doi:10.1002/rth2.12414
Davila J, Cheng D, Raffini L, Thornburg CD, Corrales-Medina FF. Characterizing the use of anticoagulants in children using the American Thrombosis and Hemostasis Network dataset (ATHNdataset). Throm Res 2021. 197: P84-87.
Degliuomini M, Colley V, Mauer E, Gerber LJ, Acharya S, Kucine N. Assessment of provider practices regarding venous thromboembolism management and prevention in pediatric acute leukemia patients. J Thromb Thrombolysis 2021. doi: 10.1007/s11239-021-02379-6.
Baumann Kreuziger L, Gaddh M, Onadeko O, George G, Wang TF, Oo TH, Sun Y, Feng M, Simpson P, Gali R, Billett HH. Treatment of catheter-related thrombosis in patients with hematologic malignancies: A Venous thromboEmbolism Network U.S. retrospective cohort study. Thrombosis Research, accepted.
Cohen AJ, Boggio L, Billett HH, DeSancho MT, Gaddh M, Kouides P, Lim M, Nyak L, Rajan S, Rosovsky R, Streiff M, Wang TF, Baumann Kreuziger L. North American Physician Practice Patterns in the Management of Anticoagulation in Pregnancy. J Womens Health (Larchmt). 2020 Nov 24. doi: 10.1089/jwh.2020.8385. Epub ahead of print. PMID: 33232187.
Baumann Kreuziger L, Gaddh M, Onadeko O, George G, Wang TF, Oo TH, Jaglal M, Houghton DE, Streiff MB, Gali R, Feng M, Simpson P, Billett HH. Treatment of catheter-related thrombosis in patients with hematologic malignancies: A Venous thromboEmbolism Network U.S. retrospective cohort study. Thromb Res. 2021 Apr 6;202:155-161. doi: 10.1016/j.thromres.2021.03.021. Epub ahead of print. PMID: 33862470.
Houghton DE, Billett HH, Gaddh M, Onadeko O, George G, Wang TF, Oo TH, Feng M, Dasgupta M, Jaglal M, Streiff MB, Simpson P, Gali R, Baumann Kreuziger L. Risk of pulmonary emboli after removal of an upper extremity central catheter associated with a deep vein thrombosis. Blood Adv. 2021 Jul 27;5(14):2807-2812. doi: 10.1182/bloodadvances.2021004698. PMID: 34264267.
Wang TF, Baumann Kreuziger L, Leader A, Spectre G, Lim MY, Gahagan A, Gangaraju R, Sanfilippo KM, Mallick R, Zwicker JI, Carrier M. Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies—TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. J Thromb Haemost. 2021;19:2068–2081.
Endorsed Studies and Clinical Trials
ATHN 15: Real world use of DOACS in pediatric patients
Prospective, observational, multi-center cohort study of venous thromboembolism outcomes in thrombocytopenic cancer patients (TROVE Study)
Real-world use of DOACs at extremes of weight: retrospective study through VENUS network
CHAT: A Multi-Institutional Children's Hospital-Acquired Thrombosis Database
Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care
Approximately 20% of patients with severe COVID-19 experience coagulopathy. Throughout this study, investigators conducted a multi-center control trial to determine the effects of therapeutic anticoagulation compared to standard hospital care for patients admitted for COVID-19.
Anti-thrombotics for Adults Hospitalized with COVID-19 (ACTIV-4)
This randomized trial compared the effectiveness of antithrombotic strategies for patients with COVID-19.
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 (ACTIV-4b)
The ACTIV-4b trial evaluated the efficacy and safety of anti-thrombotic strategies in adult COVID-19 patients who did not require hospitalization at the time of their diagnosis.
COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis
The ACTIV-4c trial is a multicenter, adaptive, randomized platform trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge.